Brian Piekos - 21 Feb 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Financial Officer
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
21 Feb 2025
Net transactions value
$0
Form type
4
Filing time
25 Feb 2025, 20:35:13 UTC
Previous filing
11 Sep 2024
Next filing
26 Nov 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Award $0 +80,000 $0.000000 80,000 21 Feb 2025 Common Stock 80,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 3/16th of the total number of shares underlying the RSUs shall vest on November 21, 2024 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.